Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDAAA Safety Labeling Powers Are Invoked Selectively But Leave Drugmakers Little Room To Maneuver

Executive Summary

FDA is being selective about when it invokes its authority under the Food and Drug Amendments Act of 2007 to require drug and biologic manufacturers to make safety-related label changes; however, when the agency does choose to act, industry has few options.
Advertisement

Related Content

Conflicting Data In Review Of New GnRH Risks
FDA Wants More REMS Authority To Speed Negotiations With Sponsors
Boxed Warning For Antipsychotics First Public Use Of FDA Labeling Authority
Boxed Warning For Antipsychotics First Public Use Of FDA Labeling Authority

Topics

Advertisement
UsernamePublicRestriction

Register

PS052879

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel